Document Detail

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
MedLine Citation:
PMID:  20065189     Owner:  NLM     Status:  MEDLINE    
PURPOSE There is no effective therapy for patients with distant metastasis of medullary thyroid carcinoma (MTC). Activating mutations in the RET proto-oncogene cause hereditary MTC, which provides a strong therapeutic rationale for targeting RET kinase activity. This open-label, phase II study assessed the efficacy of vandetanib, a selective oral inhibitor of RET, vascular endothelial growth factor receptor, and epidermal growth factor receptor signaling, in patients with advanced hereditary MTC. METHODS Patients with unresectable locally advanced or metastatic hereditary MTC received initial treatment with once-daily oral vandetanib 300 mg. The dose was adjusted additionally in some patients on the basis of observed toxicity until disease progression or any other withdrawal criterion was met. The primary assessment was objective tumor response (by RECIST [Response Evaluation Criteria in Solid Tumors]). Results Thirty patients received initial treatment with vandetanib 300 mg/d. On the basis of investigator assessments, 20% of patients (ie, six of 30 patients) experienced a confirmed partial response (median duration of response at data cutoff, 10.2 months). An additional 53% of patients (ie, 16 of 30 patients) experienced stable disease at >/= 24 weeks, which yielded a disease control rate of 73% (ie, 22 of 30 patients). In 24 patients, serum calcitonin levels showed a 50% or greater decrease from baseline that was maintained for at least 4 weeks; 16 patients showed a similar reduction in serum carcinoembryonic antigen levels. The most common adverse events were diarrhea (70%), rash (67%), fatigue (63%), and nausea (63%). CONCLUSION In this study, vandetanib demonstrated durable objective partial responses and disease control with a manageable adverse event profile. These results demonstrate that vandetanib may provide an effective therapeutic option in patients with advanced hereditary MTC, a rare disease for which there has been no effective therapy.
Samuel A Wells; Jessica E Gosnell; Robert F Gagel; Jeffrey Moley; David Pfister; Julie A Sosa; Michael Skinner; Annetta Krebs; James Vasselli; Martin Schlumberger
Related Documents :
22321199 - A score that verifies adherence to a gluten-free diet: a cross-sectional, multicentre v...
11484899 - Atypical subacute thyroiditis: preliminary observations.
1611189 - Two cases of hypothyroidism associated with alpha-interferon therapy.
9215269 - Thyroid gland abnormalities in patients with the syndrome of spotty skin pigmentation, ...
21104639 - Comparison of the prevalence and sonographic features of thyroid nodules accompanying a...
24887019 - Behcet's disease in hla-b*51 negative germans and turks shows association with hla-bw4-...
8232929 - Presentation and initial clinical course in patients with chronic inflammatory demyelin...
1445959 - Comparison of markers of coagulation activation in patients under oral anticoagulation ...
23891119 - The effects of educational background on montreal cognitive assessment screening for va...
Publication Detail:
Type:  Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't     Date:  2010-01-11
Journal Detail:
Title:  Journal of clinical oncology : official journal of the American Society of Clinical Oncology     Volume:  28     ISSN:  1527-7755     ISO Abbreviation:  J. Clin. Oncol.     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-02-09     Completed Date:  2010-03-04     Revised Date:  2012-06-04    
Medline Journal Info:
Nlm Unique ID:  8309333     Medline TA:  J Clin Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  767-72     Citation Subset:  IM    
Dept of Surgery, Washington University School of Medicine, Box 8109, 660 S Euclid Ave, St Louis, MO 63110, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Antineoplastic Agents / administration & dosage*,  adverse effects
Calcitonin / blood
Carcinoembryonic Antigen / blood
Carcinoma, Medullary / drug therapy*,  genetics,  metabolism,  mortality,  secondary
Disease-Free Survival
Drug Administration Schedule
Genetic Predisposition to Disease
Germ-Line Mutation
Kaplan-Meier Estimate
Middle Aged
Piperidines / administration & dosage*,  adverse effects
Protein Kinase Inhibitors / administration & dosage*,  adverse effects
Proto-Oncogene Proteins c-ret / antagonists & inhibitors*,  genetics
Quinazolines / administration & dosage*,  adverse effects
Risk Factors
Thyroid Neoplasms / drug therapy*,  genetics,  metabolism,  mortality,  pathology
Time Factors
Treatment Outcome
Tumor Markers, Biological / blood
United States
Young Adult
Reg. No./Substance:
0/Antineoplastic Agents; 0/Carcinoembryonic Antigen; 0/N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 0/Piperidines; 0/Protein Kinase Inhibitors; 0/Quinazolines; 0/Tumor Markers, Biological; 9007-12-9/Calcitonin; EC Proteins c-ret; EC protein, human

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-n...
Next Document:  Relationships between authorship contributions and authors' industry financial ties among oncology c...